NCT04375085: A trial that was reported late by Elixir Medical Corporation
This trial has reported, although it was 251 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04375085 |
|---|---|
| Title | A Non-Randomized, Post Marketing Clinical Follow-Up (PMCF) Study of the DESyne X2 Novolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 1, 2020 |
| Completion date | Dec. 28, 2021 |
| Required reporting date | Dec. 28, 2022, midnight |
| Actual reporting date | Sept. 5, 2023 |
| Date last checked at ClinicalTrials.gov | Aug. 1, 2025 |
| Days late | 251 |